Once weekly diabetes treatment promising in first Phase III trial

A new long-acting incretin mimetic under development for adjunctive therapy of type II diabetes has met its primary end point in a Phase III study.

Taspoglutide, like other GLP-1 analogues, is administered by subcutaneous injection.

Taspoglutide, which was discovered by Ipsen and subsequently licensed to Roche, is an analogue of glucagon-like peptide (GLP-1). This incretin hormone lowers blood glucose levels by regulating the secretion of insulin and glucagon.

Unlike the two currently approved GLP-1 analogues liraglutide (Victoza) and exenatide (Byetta), which must be given daily, taspoglutide is a weekly treatment.

The open-label T-EMERGE 2 trial tested weekly taspoglutide injections against twice daily injections of exenatide in 1189 patients with poor glycaemic control despite receiving metformin and/or a glitazone.

After 24 weeks, participants who were randomised to receive add-on treatment with taspoglutide exhibited a greater reduction in glycated haemoglobin level than those who were randomised to receive add-on therapy with exenatide.

Taspoglutide was generally well tolerated. Nausea and vomiting were the most commonly reported adverse events.

Roche plans to test taspoglutide in a total of 8 Phase III trials in more than 6000 patients.


To sign up for the MIMS monthly news update, register at www.mims.co.uk/bulletins.

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

Products coming soon - live tracker

EXCLUSIVE TO SUBSCRIBERS Monitor forthcoming UK drug...

Drug shortages - live tracker

EXCLUSIVE TO SUBSCRIBERS Use our constantly updated...

Back of man's head suffering from alopecia

Alopecia drug to be available on the NHS

In an NHS first, NICE is recommending ritlecitinib...

Stressed male GP with hand on head